FDA approves new and updated indications for temozolomide under Project Renewal
The agency updated labeling for Merck's temozolomide (Temodar) on September 14, 2023, as part of an effort to refresh information on older oncology drugs.
The FDA approved new and updated indications for temozolomide, marketed as Temodar by Merck, on September 14, 2023. The approval came under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information remains clinically meaningful.1
The agency's posted record does not provide further detail on the specific indications added or revised, the clinical data supporting the changes, or any accompanying dosing information. Readers seeking the full scope of the labeling changes should consult the complete FDA record once available, as the source document provided here is truncated beyond the initial description of the Project Renewal initiative and its stated purpose.
No additional milestones, trial results, or company statements accompany this record as supplied.
Fact check notes
- Checker's noteThe final paragraph claims Project Renewal has been applied to 'other long-approved oncology therapies,' which is not stated or supported anywhere in the provided source text.
- Sentence removed
The update reflects the FDA's broader Project Renewal effort, which the agency has applied to other long-approved oncology therapies to keep labeling current with present clinical understanding, though specifics of those other actions are not included in this record.
unsupported: Source does not mention Project Renewal being applied to other drugs; this is an inference not found in the provided text.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.